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UNIT 4.17Synthesis of Phosphorothioate
Oligonucleotides with Stereodefined
Phosphorothioate Linkages
Phosphorothioate analogs of oligonucleotides (PS-oligos) constitute an important tool for
studying the metabolism of nucleic acids (Eckstein, 2000, and references therein) and
have been evaluated as potential therapeutics in the so-called “antisense” (Stein and Krieg,
1998) and “antigene” strategies (Thuong and Helene, 1993). In 1998, the U.S. Food and
Drug Administration (FDA) approved the first PS-oligo, Fomirvirsen (trade name,
Vitravene), for therapeutic application against cytomegalovirus (CMV) retinitis (Mano-
haran, 1999). Most of the second-generation antisense compounds that are currently
undergoing clinical trials are PS-oligos (e.g., Isis Pharmaceuticals, Hybridon; Maier et
al., 2000). PS-oligos are isoelectronic with natural oligonucleotides and, importantly, they
are much more resistant towards intra- and extracellular nucleases (Wickstrom, 1986).
These features are important with respect to their therapeutic applications. However,
substitution of sulfur for one nonbridging oxygen in the internucleotide phosphate group
induces asymmetry at the phosphorus atom, and standard chemical methods for the
synthesis of oligo(deoxyribonucleoside phosphorothioate)s provide a mixture of 2n
diastereomers, where n is the number of phosphorothioate linkages (Wilk and Stec, 1995).
Therefore, even for relatively short PS-oligos (10- to 15-mers), thousands of diastereo-
mers would be involved in interactions with other chiral biomolecules (e.g., DNA, RNA,
or proteins) and, in principle, each diastereomer might interact in a slightly different
manner.
The enzymatic synthesis of PS-oligos allows for the preparation of PS-oligonucleotides
of RP-configuration at each phosphorothioate linkage (all-RP-PS-oligos) due to the
stereoselectivity of all DNA and RNA polymerases identified to date (Hacia et al., 1994;
Lackey and Patel, 1997; Tang et al., 1995). The first method for stereocontrolled chemical
synthesis of PS-oligos, which was elaborated in the authors’ laboratory (Stec et al., 1991),
is based on a new chemistry employing P-diastereomerically pure nucleoside monomers
possessing the 2-thio-1,3,2-oxathiaphospholane moiety attached to appropriately pro-
tected nucleosides at the 3′-O position (S.1; Fig. 4.17.1). Further studies resulted in the
synthesis of monomers with the oxathiaphospholane ring substituted at position 4 with
either two methyl groups (S.2; Stec et al., 1995) or a spiro pentamethylene ring (S.3; Stec
et al., 1998). These substituents enhance a differentiation in chromatographic mobility of
diastereomers, rendering their separation less laborious. The oxathiaphospholane mono-
mers react in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) with the 5′-OH
group of a nucleoside (or growing oligonucleotide attached at the 3′ end to a DBU-resis-
tant solid support) to yield a dinucleotide (or an elongated oligomer) with an internu-
cleotide phosphorothioate diester bond, as depicted in Figure 4.17.2. The process is fully
stereospecific and occurs with retention of configuration at the phosphorus atom. The
chemical yield of the condensation process is not as efficient as that of the phos-
phoramidite or H-phosphonate methods (UNITS 3.3 & 3.4), but repetitive yields of 92% to
94% allow syntheses of medium-sized oligomers (up to 15-mers). Longer oligonu-
cleotides were obtained in poor yields and the syntheses were not reproducible. Oxathia-
phospholanes that are 18O-labeled at the endocyclic position allowed for the synthesis of
PS-oligos with internucleotide PS[18O]-phosphorothioate moieties of predetermined
chirality (Guga et al., 2001).
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For the synthesis of stereodefined PS-oligos via the oxathiaphospholane methodology
presented in this unit, pure P-diastereomers of nucleoside oxathiaphospholane monomers
are required. They are not commercially available, but can be efficiently obtained by
phosphitylation of widely available 5′-O-DMTr-N-protected deoxyribonucleosides with
oxathiaphospholane phosphitylating reagent followed by sulfurization. The methodology
of their synthesis and use in solid-phase synthesis of PS-oligos is presented in consecutive
protocols.
Basic Protocol 1 describes a detailed procedure for the synthesis of the phosphitylating
reagent 2-chloro-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane. The procedure is
general and may be applied to other analogs, depending on the aldehyde (or mercaptoal-
cohol) used.
Alternate Protocol 1 describes a procedure for synthesis of 18O-labeled mercaptoalcohol,
which is used to synthesize labeled phosphitylating reagent and, subsequently, 18O-la-
beled nucleoside monomers. These can be used for synthesis of stereodefined PS[18O]-
oligos, which are useful compounds in studying the mechanism(s) of enzymatic reactions.
Support Protocol 1 describes a method for transfer of dry solvents, required for this
procedure.
Basic Protocol 2 outlines the synthesis of 5′-O-DMTr-N-protected-deoxyribonucleoside-
3′-O-(2-thio-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane)s (S.3)  and their
chromatographic separation into P-diastereomers. This method, although described for
dA, dC, dG, and T derivatives, can be also used for derivatizing other appropriately
protected nucleosides. For example, in the authors’ laboratory, N6-benzoyl-7-deaza-5′-O-
(4,4′-dimethoxytrityl)-3′-O-(2-thio-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane)-
2′-deoxyadenosine was obtained and separated into diastereomers (unpub.). Similarly,
this method is suitable for phosphitylation of protected nucleosides with other oxathia-
phospholane reagents containing different substituents, although the separation of dias-
tereo-mers may be very difficult.
Alternate Protocol 2 describes the conversion of 5′-O-DMTr-N-protected-deoxyribonu-
cleoside-3′-O-(2-thio-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane)s to their 2-
oxo-analogs with selenium dioxide. These monomers can be used to elongate
stereodefined PS-oligos and generate segments of unmodified nucleotide units possessing
phosphate internucleotide linkages. This goal cannot be achieved with the phos-
phoramidite or H-phosphonate methods, because the phosphorothioate linkages already
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Figure 4.17.1 Structural features of deoxyribonucleoside oxathiaphospholane derivatives. Abbre-
viations: B, thymin-1-yl or N-protected nucleobase; DMTr, 4,4′-dimethoxytrityl. Adapted from Stec
et al. (1998) with permission from the American Chemical Society.
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generated by the oxathiaphospholane method are diesters and would be oxidized in the
I2/water/pyridine routinely used for conversion of phosphites to phosphates.
Basic Protocol 3 outlines details of manual solid-phase synthesis of PS-oligos using
oxathiaphospholane monomers. In principle, this synthesis can be performed on an
automatic synthesizer, but the necessary modification of the manufacturer’s protocols is
impossible for the majority of synthesizers. The protocol for 1-µmol-scale automated
solid-phase synthesis using an ABI 391 synthesizer (Applied Biosystems) has been
published (Stec et al., 1998), but in many instances the software does not allow for any
changes in the protocol. Also, the instrument should be able to deliver an additional solvent
(methylene chloride) to the column in order to wash delivery lines after coupling. This is
necessary to avoid formation of deposits inside the tubing and valves, which may lead to
major failure of the instrument and expensive replacement of the clogged valve blocks.
One also has to consider that, in using an automated synthesizer, significant amounts of
monomer solutions are wasted during optimization of the protocol, and due to the dead
volumes of the system. Therefore, manual synthesis of a limited number of oligomers
may be economically more justified.
Support Protocol 2 describes preparation of solid supports for the synthesis of PS-oligos,
which must be DBU-resistant because this strong base is necessary for the coupling step.
This requirement is fulfilled by the use of Brown’s sarcosinyl-succinoyl linker (Brown et
al., 1989).
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Figure 4.17.2 Mechanism of base-promoted oxathiaphospholane ring-opening condensation. Abbreviations: B, thymin-1-
yl or N-protected nucleobase; DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene; DMTr, 4,4′-dimethoxytrityl; ψ, pseudorotation; Sar,
sarcosinylated or DBU-resistant solid support.
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CAUTION: It is imperative that all reactions be run in a suitable fume hood with efficient
ventilation. Many of the reactions in this unit are highly exothermic; safety glasses and
reagent-impermeable protective gloves should be worn.
BASIC
PROTOCOL 1
SYNTHESIS OF PHOSPHITYLATING REAGENT: 2-CHLORO-spiro-4,4-PEN-
TAMETHYLENE-1,3,2-OXATHIAPHOSPHOLANE
The most simple oxathiaphosphitylating reagent, 2-chloro-1,3,2-oxathiaphospholane,
can be obtained from the reaction of 2-mercaptoethanol with phosphorus trichloride in
the presence of two molar equivalents of triethylamine (Martynov et al., 1969; Willson et
al., 1975; Stec et al., 1991). Condensation of an appropriately protected 3′-OH-nucleoside
with 2-chloro-1,3,2-oxathiaphospholane in pyridine solution, performed in the presence
of dry elemental sulfur, provides nucleoside 3′-O-(2-thiono-1,3,2-oxathiaphospholane)s
(S.1; Fig. 4.17.1). However, their separation as P-diastereomers is very laborious and
requires several consecutive silica gel chromatographic runs of partially enriched frac-
tions. Therefore, it is recommended to synthesize 2-chloro-spiro-4,4-pentamethylene-
1,3,2-oxathiaphospholane (S.9) starting from cyclohexanecarboxaldehyde (S.5), as
depicted in Figure 4.17.3. Using isobutyraldehyde in the same sequence of reactions,
2-chloro-4,4-dimethyl-1,3,2-oxathiaphospholane can be obtained. However, the
phosphitylating reagent S.9, when used for synthesis of nucleotide monomers, provides
much more useful compounds in terms of chromatographic separability as pure P-dia-
stereomers. It is important to note that the fast-eluting isomers of 4,4-dimethyl- and
4,4-pentamethylene-oxathiaphospholane monomers are precursors of RP internucleotidic
phosphorothioate bonds. Conversely, analog internucleotide phosphorothioate bonds of
RP configuration are formed from the slow-eluting isomer of S.1.
Using this methodology, different analogs can be synthesized. However, it is important
to obtain a phosphitylating reagent without additional centers of asymmetry, as the
number of diastereomers will double with each new center, rendering separation of
P-diastereomers very difficult or impossible. The relationship between chromatographic
mobility and absolute configuration of the monomers must be checked for each new
analog.
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Figure 4.17.3 Synthesis of 2-chloro-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane (S.9)
starting from cyclohexanecarboxaldehyde (S.5). Adapted from Stec et al. (1998) with permission
from the American Chemical Society.
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Materials
4 to 5 M and 1.5 M sodium hydroxide (NaOH)
Sulfur monochloride (S2Cl2), freshly distilled over 2 g elemental sulfur (S8; dried
≥12 hr under vacuum) per 50 mL S2Cl2
Argon (or, optionally, nitrogen), dry
Cyclohexanecarboxaldehyde (Fluka)
Methylene chloride
Diethyl ether, anhydrous
Sodium borohydride (NaBH4)
Isopropyl alcohol
Anti-bumping granules
20% (w/v) hydrochloric acid
Chloroform
Magnesium sulfate, anhydrous
Hexane
Lithium aluminum hydride
Ethyl acetate, dry
Tetrahydrofuran (THF), with traces of added moisture
10% (v/v) H2O/THF
Phosphorus trichloride (PCl3)
Benzene, anhydrous
Pyridine
Dry molecular sieves (4A, 4- to 6-µm-o.d. beads, Aldrich)
250-mL absorber with safety flask (see Fig. 4.17.4)
250-mL four-neck round-bottom flask
Heated oil bath capable of magnetic stirring
Thermometer (capable of reading 150°C)
100-mL dropping funnel
Reflux condensers
Glass gas inlet adapter (preferred) or syringe needle and rubber septum
Rotary evaporator with a water aspirator and a diaphragm vacuum pump (10 to 15
mmHg; optional)
500-mL Erlenmeyer flask (29/42 joint)
1-L two-neck round-bottom flask (two 29/42 joints)
Stopcock, 29/42
Flexible adapter (glass M/F joints, 29/42, on corrugated Teflon tubing; optional)
500-mL separatory funnel
Filter funnel and Whatman no.1 filter paper (or equivalent)
High-vacuum fractional distillation apparatus
High-vacuum oil pump (0.01 mmHg)
NOTE: Upon storage, cyclohexanecarboxaldehyde undergoes polymerization. Order only
the amount required for use within 2 to 3 weeks.
NOTE: Within this unit, evaporation of solvents is performed using a rotary evaporator
connected to a water aspirator, unless otherwise specified.
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Synthesize 2,2′-dithiobis(cyclohexanecarbaldehyde) (S.6)
1. Prepare a 250-mL absorber containing ∼150 mL of 4 to 5 M NaOH (see Fig. 4.17.4).
2. Assemble a reactor consisting of a 250-mL four-neck, round-bottom flask (to be
heated in an oil bath with magnetic stirring) equipped with a thermometer, a 100-mL
dropping funnel, a condenser, and a magnetic stir bar. Connect the outlet of the
condenser via a safety flask to the absorber and be sure that the absorber vents into
the hood.
The capacity of the safety flask must be sufficient to accommodate the solution of sodium
hydroxide from the absorber.
3. Add 30 g (17.8 mL, 0.22 mol) of freshly distilled sulfur monochloride to the flask.
Make sure that the thermometer is in contact with the liquid. Deliver dry argon close
to the bottom of the flask through the fourth joint either with a glass gas inlet adapter
or with a syringe needle inserted through a rubber septum.
Since gaseous hydrogen chloride is liberated from the reaction, the use of a glass inlet
adapter, rather than a syringe needle, is recommended.
4. Apply heating until sulfur monochloride reaches 60°C. Stabilize the temperature.
5. Add, dropwise through the dropping funnel, 50 g (56 mL, 0.44 mol) of cyclohexane-
carboxaldehyde over a 60-min period with stirring, keeping the temperature at 60°C.
Remove the oil bath and allow the mixture to continue stirring another 10 min.
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Figure 4.17.4 System assembly for synthesis of S.6. The glass gas adapter (or septum and
needle) for delivery of dry argon should be mounted in the fourth neck of the flask (not shown).
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6. Stop stirring and remove the stir bar. Leave the reaction mixture until it reaches room
temperature and solidifies (∼1 hr).
7. Dissolve the solid residue in 150 mL of methylene chloride, then evaporate to dryness
using a rotary evaporator connected to a water aspirator.
CAUTION: During evaporation gaseous hydrogen chloride is liberated.
8. Add 150 mL of diethyl ether and gently reflux until the solid residue is dissolved.
Transfer the solution into a 500-mL Erlenmeyer flask and close the stopcock. Cool
down the mixture (containing the synthesized S.6) and keep overnight in a refrigerator
(4°C) to allow crystallization. Collect crystalline S.6 by filtration.
Approximately 35 g of 2,2′-dithiobis(cyclohexanecarbaldehyde) (S.6) should be collected
as a white solid (∼70% yield, m.p. 88° to 89°C). 1H NMR (CDCl3, δ): 8.98 ppm (s, 1H,
CHO), 1.2-2.1 ppm (m, 10H). FAB MS (positive mode, Cs+, 13 keV, matrix NBA) m/z 286,
[M]+, 25%; m/z 111, [C6H10CHO]+, 100%.
Synthesize 2,2′-dithiobis(cyclohexanemethanol) (S.7)
9. In a 1-L two-neck flask (two 29/42 joints), equipped with a reflux condenser and a
stopcock, suspend 5.67 g (0.15 mol) of NaBH4 in 500 mL isopropyl alcohol. Add
anti-bumping granules and heat to boiling.
10. While gently refluxing, remove the stopcock momentarily and add, with a chemical
spoon, ∼2 g of S.6 every 3 to 5 min in 10 to 12 portions for a total of 21.5 g (0.075
mol).
CAUTION: The addition of each portion of 2,2′-dithiobis(cyclohexanecarboxaldehyde)
results in enhanced boiling and emission of vapors of isopropyl alcohol through the open
neck. The stopcock should thus be closed as soon and possible. Alternatively, one can use
a flexible adapter (glass M/F joints on corrugated Teflon tubing) for stepwise delivery of
2,2′-dithiobis(cyclohexanecarboxaldehyde) without opening the reactor.
11. Reflux the mixture for 1 hr, then evaporate to dryness and add 200 mL of 1.5 M
sodium hydroxide.
12. Cautiously neutralize the mixture with 20% hydrochloric acid, checking pH with
indicator strips.
13. Transfer the mixture to a 500-mL separatory funnel and extract the solution twice,
each time with 150 mL chloroform. Dry the organic layer with anhydrous magnesium
sulfate and evaporate the solvent.
14. Dissolve the product in 200 mL of diethyl ether and add, with stirring, a few 3- to
5-mL aliquots of hexane until the mixture becomes translucent. Leave in a refrigerator
(4°C) overnight for crystallization. Collect crystalline S.7 by filtration.
Approximately 19 g of 2,2′-dithiobis(cyclohexanemethanol) (S.7) should be collected as a
colorless crystalline material (85% to 88% yield, m.p. 49° to 50°C). 1H NMR (CDCl3, δ):
3.54 ppm (s, 2H, CH2OH), 2.23 ppm (s, 1H, CH2OH), 1.2-1.8 ppm (m, 10H). 13C NMR
(CDCl3, δ): 21.9, 25.73, 32.45, 56.18, 67.99 ppm. FAB MS (positive mode, Cs+, 13 keV,
matrix NBA) m/z 290, [M]+, 45%; m/z 273, [M-OH]+, 25%; m/z 113, [C6H10CH2OH]+,
100%.
Synthesize 2-mercaptocyclohexanemethanol (S.8)
15. In a 1-L two-neck flask equipped with a reflux condenser and a dropping funnel
(atmosphere of dry argon or nitrogen) suspend 5.9 g (0.16 mol) lithium aluminum
hydride in 500 mL of dry diethyl ether.
CAUTION: The suspension of lithium aluminum hydride in diethyl ether is highly flam-
mable. Advise coworkers of the hazard and keep an appropriate fire extinguisher at hand.
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16. Add dropwise through the dropping funnel a solution of 4.6 g (0.16 mol) S.7 in 150
mL of diethyl ether over 60 min with magnetic stirring. Continue stirring for an
additional 60 min.
The reaction is exothermic and mild reflux occurs.
17. Cautiously decompose excess reducing agent by adding dropwise through the funnel
3 mL of dry ethyl acetate, followed by 10 mL THF containing traces of moisture, and
then ∼10 mL of 10% water/THF, until the solid suspension becomes gray and finally
white.
18. Filter off inorganic salts using a filter funnel and Whatman no. 1 filter paper, and dry
the filtrate over anhydrous magnesium sulfate. Filter off the drying agent and
evaporate the filtrate to dryness.
19. Distill the residue in a high-vacuum fractional distillation apparatus under reduced
pressure (0.05 mmHg, provided by high-vacuum oil pump). Collect the fraction
boiling between 74° and 76°C, which contains S.8.
CAUTION: Avoid overheating the vessel. Keep pressure below 0.1 mmHg.
Approximately 3.2 g of 2-mercaptocyclohexanemethanol (S.8) should be collected as a
colorless oil (70% yield, nD20 = 1.5188). 1H NMR (CDCl3, δ): 3.49 ppm (s, 2H, CH2OH),
2.15 ppm (bs, 1H, CH2OH), 1.31 ppm (s, 1H, CHSH), 1.15-1.85 ppm (m, 10H). 13C NMR
(CDCl3, δ): 22.0, 26.07, 36.06, 52.34, 73.12 ppm. FAB MS (negative mode, Cs+, 13 keV,
matrix GLY) m/z 145, [M]–, 100. FAB MS (positive mode, Cs+, 13 keV, matrix GLY) m/z
113, [C6H10CH2OH]+, 45%; m/z 129, [C6H10SHCH2]+, 20%.
Synthesize 2-chloro-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane (S.9)
20. In a 1-L two-neck flask equipped with a thermometer and a dropping funnel, add 28.2
g (0.21 mol) PCl3 to 500 mL of dry benzene under an argon (optionally nitrogen)
atmosphere. Cool the flask to 5°C with an ice bath. Add, dropwise through the funnel,
a solution of 20 g (0.14 mol) S.8 and 22 mL (0.27 mol) pyridine in 35 mL dry benzene
over a 15-min period with magnetic stirring. Keep the temperature of the reaction
mixture below 10°C.
21. Continue stirring at room temperature for 30 min and filter off pyridine hydrochloride
with exclusion of moisture. Load the reaction mixture in a filter funnel inside a bag
filled with dry argon (or nitrogen) and gently apply suction to keep the bag slightly
inflated with continuous delivery of dry gas.
22. Evaporate the solvent under reduced pressure with exclusion of moisture (preferably
in a rotary evaporator equipped with a diaphragm vacuum).
If a water aspirator must be used, insert a drying tube filled with blue indicator silica gel
between the rotary evaporator and the aspirator to reduce the risk of hydrolysis of the
product. Apply vacuum gently.
23. Distill the product in a high-vacuum fractional distillation apparatus under reduced
pressure (0.01 mmHg, provided by a high-vacuum oil pump). Collect the fraction
boiling between 82° and 84°C, which contains S.9.
CAUTION: Avoid overheating the vessel. Keep pressure at 0.01 mmHg. When overheated,
spontaneous decomposition of the crude product may occur, leading to destruction of the
apparatus.
Approximately 20 g of 2-chloro-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane (S.9)
should be collected as a colorless liquid (70% to 75% yield). 31P NMR (C6D6; δ) 217.7
ppm; EI (electron impact) MS: (70 eV) m/z 210, [M]+, 12%; m/z 175, [M-Cl]+, 5.8%; m/z
90, 100%.
24. Store S.9 in a tightly closed vessel inside another tightly closed container filled with
several grams of dry 4A molecular sieves at –20°C (stable for at least 1 year).
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ALTERNATE
PROTOCOL 1
SYNTHESIS OF 2,2′-DITHIOBIS([18O]CYCLOHEXANECARBOXALDEHYDE)
The 18O-labeled 2,2′-dithiobis(cyclohexanecarboxaldehyde), which can be further trans-
formed into the corresponding phosphitylating reagent as described in Basic Protocol 1,
is obtained by hydrolysis of the N-phenylimine derivative of 2,2′-dithiobis(cyclohexane-
carboxaldehyde) with H2[18O], catalyzed with gaseous hydrogen chloride (Fig. 4.17.5).
The N-phenylimine derivative is obtained from 2,2′-dithiobis(cyclohexanecarboxalde-
hyde) (S.6; see Basic Protocol 1, step 8) upon treatment with aniline.
Additional Materials (also see Basic Protocol 1)
2,2′-Dithiobis(cyclohexanecarboxaldehyde) (S.6; see Basic Protocol 1, step 8)
Aniline, freshly distilled in inert atmosphere
95:5 (v/v) chloroform/hexane
H2[18O] (95 atom%)
Hydrogen chloride, anhydrous
Tetrahydrofuran (THF), dried over sodium hydride
250-mL two-neck round-bottom flasks
Azeotropic trap (e.g., mini Dean-Stark trap, Aldrich)
8 × 40–cm chromatography column packed with silica gel 60, 230 to 400 mesh
(Merck)
Rubber septum
TLC silica gel plates with UV indicator (Merck; also see APPENDIX 3D)
High vacuum valve (e.g., Rotaflo, Quickfit)
Drying tube (8 × 5⁄8 in. with connectors, Aldrich)
2- to 5-mL gas-tight syringe
Rotary evaporator with water aspirator or membrane pump
Buchner funnel with glass frit
Additional reagents and equipment for column chromatography (APPENDIX 3E),
thin-layer chromatography (TLC; APPENDIX 3D), and high-vacuum transfer of
solvent (see Support Protocol 1)
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Figure 4.17.5 Synthesis of 2-chloro-spiro-4,4-pentamethylene-1,3,2-[18O]oxathiaphospholane
(S.12) starting from 2,2′-dithiobis(cyclohexanecarboxaldehyde) (S.6).
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Synthesize N-phenylimine derivative of 2,2′-dithiobis(cyclohexanecarboxaldehyde)
(S.10)
1. In a 250-mL two-neck flask equipped with an azeotropic trap, reflux condenser, and
dropping funnel, dissolve 14.3 g (0.05 mol) of 2,2′-dithiobis(cyclohexanecarboxal-
dehyde) (S.6) in 150 mL benzene. Add anti-bumping granules and heat to boiling.
2. Add, dropwise through the dropping funnel, a solution of 10.0 mL (10.2 g, 0.11 mol)
aniline in 25 mL benzene over a 30-min period. Continue the reaction for 30 min,
keeping gently boiling with azeotropic removal of liberated water.
The end of the reaction is confirmed by disappearance of a resonance line of the aldehyde
proton in the 1H NMR spectrum.
3. Cool the reaction mixture to room temperature and evaporate the solvent under
reduced pressure using a rotary evaporator with a water aspirator.
4. Dissolve the residue in 15 to 20 mL of benzene and apply to an 8 × 40–cm
chromatography column packed with ∼200 g of 230 to 400 mesh silica gel.
5. Elute the column with chloroform and collect the eluate in 12- to 15-mL fractions.
6. Analyze fractions by TLC on silica gel plates (APPENDIX 3D). Develop TLC plates with
95:5 (v/v) chloroform/hexane.
7. Combine all fractions that contain the desired product (S.10; Rf = 0.55). Evaporate
the solvent under reduced pressure.
Typically 18 g (80% yield) of the N-phenylimine derivative (S.10; see Fig. 4.17.5) should
be obtained. 1H NMR (CDCl3, δ): 6.67-6.80 ppm (m, 1H), 7.07-7.55 ppm (m, 4H), 3.6 ppm
(very broad singlet, 1H, CH=NPh), 1.29-2.18 ppm (m, 10H). 13C NMR (CDCl3, δ): 22.8,
24.88, 25.22, 30.05, 30.15, 33.23, 56.13, 56.793, 60.13, 60.62, 76.38, 77.01, 77.65, 114.84,
118.14, 120.63, 120.69, 125.42, 125.69, 128.11, 128.78, 129.00, 146.28, 150.99, 151.33,
164.78, 165.62, 194.09, 194.77. This number of resonances in the 13C NMR spectrum
reflects the presence of cis- and trans-isomers of the N-phenylimine derivative.
Synthesize labeled 2,2′-dithiobis([18O]cyclohexanecarboxaldehyde) (S.11)
8. Place 16 g (0.037 mol) S.10 in a 250-mL two-neck round-bottom flask with a
magnetic stir bar inside, with a high-vacuum valve in one joint and a rubber septum
in the other, and dry overnight at high vacuum (0.01 mmHg; provided by high-vacuum
oil pump). At the end of drying, deliver dry argon gas to the flask through the septum.
9. Prepare an absorber containing ∼150 mL of 4 to 5 M NaOH (see Basic Protocol 1,
step 1).
10. Using the vacuum line technique (see Support Protocol 1), transfer ∼100 mL of dry
THF to the flask containing S.10.
11. Connect the vacuum valve with the absorber through an 8 × 5⁄8–in. drying tube (filled
with anhydrous magnesium sulfate) and a safety flask (Fig. 4.17.4).
12. Add 1.8 mL (0.9 mol) H2[18O] (20% excess) with a 2- to 5-mL gas-tight syringe.
13. Flush the apparatus continously with dry argon and cool the mixture to <5°C in an
ice bath.
14. Remove the septum and quickly install a glass gas inlet adapter for delivery of
hydrogen chloride. Adjust the adapter so that its end is ∼1.5 to 2 cm above the level
of the liquid.
15. Slowly deliver anhydrous hydrogen chloride with magnetic stirring of the mixture.
Precipitation of anilinium hydrochloride should be observed during this process.
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16. Continue hydrolysis until the reaction mixture becomes pale green-yellow. Remove
ice bath and allow the mixture to reach room temperature.
17. Filter off the precipitate using a Buchner funnel. Wash twice with 20 to 30 mL THF.
18. Combine filtrates and evaporate solvent under reduced pressure.
CAUTION: The THF vapor will be strongly acidic, as it is saturated with hydrogen
chloride.
19. Dissolve the residue in 100 mL of THF and evaporate the solvent again.
20. Dissolve the residue in diethyl ether and crystallize by cooling (see Basic Protocol
1, step 8).
21. Analyze the product using electron impact (EI) mass spectrometry.
Each aldehyde group of the final product is isotopically labeled to the extent of 87%. The
spectrum should contain three peaks at m/z 286, 288, and 290, corresponding to the
unlabeled, singly labeled, and doubly labeled compounds, respectively. The intensities of
the ions are 1.7%, 22.6%, and 75.7%, respectively. The isotope content remains unchanged
during subsequent reactions leading to the final phosphitylating reagent.
22. Continue the synthesis (see Basic Protocol 1, starting from step 9).
SUPPORT
PROTOCOL 1
HIGH-VACUUM TECHNIQUE FOR TRANSFER OF DRY SOLVENTS
This technique allows for transfer of dry solvents from a reservoir (where the solvent is
stored over a drying reagent such as sodium hydride) into a reaction flask with exclusion
of moisture. For successful transfer, the quality of vacuum valves is absolutely essential.
Figure 4.17.6 shows principal construction of the apparatus, which can be assembled from
generic glassware. All components must be tested to make sure that they are safe for
high-vacuum usage (i.e., at <0.5 mmHg).
1. Set up the apparatus as shown in Fig. 4.17.6, but leave the flask containing THF over
NaH not yet immersed in the warm water bath and the receiving flask not yet
immersed in the dry ice/isopropanol bath.
2. Close high-vacuum valves A and B.
3. Attach the apparatus to high vacuum (<0.5 mmHg).
4. Open valve B for several seconds.
5. Close valve B.
6. Open valve A for several seconds. If gentle boiling of THF is observed, go to step 9.
7. Close valve A.
8. Decrease the pressure in the system by repeating steps 4 to 7.
9. While valve B is closed, immerse the receiving flask in the dry ice/isopropanol bath.
10. Immerse the reservoir in the warm water bath (∼50° to 55°C). Alternatively, use a
hair dryer to provide heat to the reservoir.
11. After the required volume of solvent has been transferred, stop heating and remove
the dry ice bath. Allow both flasks to reach ambient temperature.
12. Disconnect the apparatus from the high vacuum and attach the outlet to a line with
dry argon.
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13. Open valve B and fill the system with argon.
14. Close valves A and B.
15. Disconnect the flask with transferred solvent and close immediately with a stopcock
or septum.
BASIC
PROTOCOL 2
SYNTHESIS OF 5′-O-DMTr-DEOXYRIBONUCLEOSIDE-3′-O-(2-THIO-4,4-
spiro-PENTAMETHYLENE-1,3,2-OXATHIAPHOSPHOLANE)S AND THEIR
SEPARATION INTO P-DIASTEREOMERS
The oxathiaphospholane method of stereocontrolled synthesis of PS-oligos, depicted in
Figure 4.17.2, is based on availability of diastereomerically pure oxathiaphospholane
monomers S.1-S.3. Separation of monomers S.1 and S.2 as pure P-diastereomers requires
tedious silica gel column chromatography or costly preparative HPLC. Monomer S.3,
obtained by introducing a pentamethylene substituent at position 4 of the oxathiaphos-
pholane ring, possesses a satisfactory separability of diastereomers. Appropriate 5′-O-
DMTr-N-protected deoxyribonucleosides are phosphitylated at room temperature with
S.9 or S.12 in acetonitrile, in the presence of diisopropylethylamine, to yield the corre-
sponding phosphites, which are further sulfurized with elemental sulfur. Silica gel column
chromatography affords S.3 (or its 18O-labeled analog) as a diastereomeric mixture in
satisfactory yield (75% to 85%). The deoxyguanosine derivative of S.3 should be
additionally protected at O6 with diphenylcarbamoyl chloride to improve the yield of the
condensation step. Without this protection, the repetitive yield of condensation of the
deoxyguanosine oxathiaphospholane monomer drops below 90%. The S.3 monomers (B
= T, ABz, CBz, Gi-Bu,DPC) are separated by column chromatography into fast- and slow-
eluting species. The stereochemistry of the coupling has been checked for each of 32
combinations of diastereomeric dinucleotides NPSN (N = dG, dA, dC, T). All four
fast-eluting diastereomers of S.3 are precursors of the dinucleoside 3′,5′-phos-
phorothioates of RP configuration. Slow-eluting isomers of S.3 yield phosphorothioate
linkages of SP configuration.
valve A
valve B
to high vacuum
warm water bath
THF over NaH
dry ice/isopropanol bath
Figure 4.17.6 Apparatus for high-vacuum transfer of dry solvents.
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NOTE: It is important to use acid-free eluents for all silica gel chromatography of the
monomers to avoid partial detritylation of the products. This can be done by distillation
of chloroform with 1 mL pyridine, and then by adding 2 to 3 mL pyridine per liter of all
eluents (chloroform and mixtures of ethyl acetate, butyl acetate, and benzene).
Materials
5′-O-DMTr-N-protected deoxyribonucleosides (Chemgenes):
 N6-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyadenosine (5′-O-DMTr-dABz)
 N2-Isobutyryl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxyguanosine
(5′-O-DMTr-dGi-Bu)
 N4-Benzoyl-5′-O-(4,4′-dimethoxytrityl)-2′-deoxycytidine (5′-O-DMTr-dCBz)
 5′-O-(4,4′-Dimethoxytrityl)-2′-deoxythymidine (5′-O-DMTr-T)
Argon (or, optionally, nitrogen), dry
Acetonitrile, anhydrous
2-Chloro-spiro-4,4-pentamethylene-1,3,2-oxathiaphospholane (S.9 or labeled
S.12; see Basic Protocol 1 or Alternate Protocol 1)
Elemental sulfur, anhydrous (dried overnight at high vacuum)
Chloroform (distilled with 1 mL pyridine per L)
Toluene, dry
Pyridine, anhydrous
Diisopropylethylamine (Aldrich), anhydrous
Diphenylcarbamoyl chloride (Aldrich)
9:1 (v/v) chloroform/methanol
Merck 60H silica gel, particle size 5 to 40 µm
Ethyl acetate
Butyl acetate
Benzene
25-mL two-neck round-bottom flasks
High-vacuum valve (Rotaflo, Quickfit)
Rubber septum
High-vacuum oil pump (0.01 mmHg)
2-mL and 10-mL gas-tight syringes
Buchner funnel
25 × 3–cm chromatography column packed with 20 g of 230 to 400 mesh silica gel
TLC silica gel plates with UV indicator (Merck; also see APPENDIX 3D)
Constant temperature water bath
30 × 2–cm chromatography column
Filter paper (Whatman no. 1)
High-performance TLC (HP-TLC) plates (silica gel 60 F254) with UV indicator
(Merck; also see APPENDIX 3D)
Additional reagents and equipment for column chromatography (APPENDIX 3E) and
thin-layer chromatography (TLC; APPENDIX 3D)
Phosphitylate protected deoxyribonucleosides
1. Place 10 mmol of 5′-O-DMTr-N-protected deoxyribonucleoside (dABz, dGi-Bu, T, or
dCBz) in a 25-mL two-neck round-bottom flask containing a magnetic stir bar, with
a high-vacuum valve in one joint and a rubber septum in the other, and dry overnight
at high vacuum (0.01 mmHg; provided by high-vacuum oil pump).
2. Close the vacuum valve and fill the flask with dry argon (optionally nitrogen).
3. Using a gas-tight syringe, add 10 mL of anhydrous acetonitrile through the septum.
4. Using a gas-tight syringe, add 1.91 mL (11 mmol) of anhydrous diisopropylethyl-
amine.
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5. To the magnetically stirred solution, using a gas-tight syringe, add dropwise at room
temperature 1.63 mL (2.32 g, 11 mmol) of 2-chloro-spiro-4,4-pentamethylene-1,3,2-
oxathiaphospholane (S.9) over a 5-min period.
6. Stir an additional 5 min and add ∼0.5 g (∼15 mmol) dry elemental sulfur. Continue
stirring for 12 hr.
7. Filter off excess sulfur using a Buchner funnel. Evaporate the solvent and dissolve
the residue in 4 mL of chloroform (distilled with pyridine).
8. Apply crude product to a 25 × 3–cm column packed with 20 g of 230 to 400 mesh
silica gel. Elute the column with chloroform, collecting 8- to 10-mL fractions.
Identify the appropriate fractions by TLC (APPENDIX 3D) using standard silica gel plates
and 95:5 (v/v) CHCl3/methanol (Rf = 0.6575). Combine fractions and evaporate the
solvents under reduced pressure (15 to 20 mmHg) with a water bath temperature not
exceeding 30°C.
9. Add 5 to 6 mL of dry toluene and evaporate to dryness with exclusion of moisture
using a membrane pump. Repeat this step twice.
After the solvent is evaporated, apply high vacuum to the flask for 2 hr. Close the flask with
a septum and pierce the septum with a needle. Store the flask in a desiccator and apply
high vacuum for ≥12 hr. The monomers can be stored at room temperature in a desiccator
for a month.
The desired 5′-O-DMTr-deoxyribonucleoside-3′-O-(2-thio-spiro-4,4-pentamethylene-
1,3,2-oxathiaphospholane)s are obtained in 75% to 85% yield. For the guanosine deriva-
tive, diphenylcarbamoyl protection at O6 is required (steps 10 to 15). The diastereomeric
composition, 31P NMR chemical shifts, and TLC parameters (HP-TLC plates) of com-
pounds S.3a to c are given in Table 4.17.1. Elemental analysis (found/calculated): S.3a (B
= T) C 61.67%/60.79%, H 6.15%/5.77%, N 3.73%/3.73%, P 4.06%/4.13%, S
8.00%/8.54%; S.3b (B = ABz) C 62.84%/62.56%, H 5.48%/5.37%, N 7.73%/8.11%, P
3.41%/3.58%, S 6.74%/7.42%; S.3c (B = CBz) C 62.53%/62.92%, H 5.47%/5.52%, N
5.14%/5.00%, P 3.65%/3.69%, S 7.26%/7.63%.
Table 4.17.1 Characteristics of the 5′-O-DMTr-deoxyribonucleoside-3′-O-(2-thio-spiro-4,4-
pentamethylene-1,3,2-oxathiaphospholane)sa
Base Yield (%) Composition(fast:slow)
δP
(ppm, CD3CN) Rf (TLC)
b
T (3a) 84 50:50 105.3 (fast)
105.6 (slow)
0.61 (fast)
0.54 (slow)
ABz (3b) 84 49:51 104.7 (fast)
105.1 (slow)
0.54 (fast)
0.46 (slow)
CBz (3c) 86 48:52 105.3 (fast)
105.6 (slow)
0.60 (fast)
0.40 (slow)
Gi-Bu,DPC (3d) 78 52:48 106.2 (fast)d
106.9 (slow)d
0.37 (fast)c 
0.26 (slow)c 
aTable adapted from Stec et al. (1998) with permission from the American Chemical Society.
bTLC performed on HP-TLC plates with UV indicator (Merck) and a developing system of 1:1 (v/v) butyl acetate/benzene
(T and Gi-Bu) or 1:2 (v/v) ethyl acetate/butyl acetate (ABz and CBz).
cRf values reported for monomers before O6-protection with diphenylcarbamoyl chloride (DPC). After protection, Rf
values are 0.74 and 0.63 using the same solvent system.
dδP values reported for monomers after O6-protection with DPC.
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Perform O6 protection of deoxyguanosine derivative
10. Place 0.85 g (1 mmol) of N2-isobutyryl-5′-O-(4,4′-dimethoxytrityl)-3′-O-(2-thio-
spiro-4,4-pentamethylene-1,3,2-oxathiaphospholanyl)-2′-deoxyguanosine (from
step 9) in a two-neck 25-mL round-bottom flask with a magnetic stir bar, with a
high-vacuum valve in one neck and a rubber septum in the other, and dry overnight
at high vacuum (0.01 mmHg).
11. Using a 10-mL gas-tight syringe, add 5 mL of anhydrous pyridine.
12. Using a 2-mL gas-tight syringe, add 0.26 mL (1.5 mmol) diisopropylethylamine and
0.46 g (2.0 mmol) diphenylcarbamoyl chloride, with stirring, at room temperature.
Continue stirring mixture 1 hr.
13. Concentrate mixture to dryness, dissolve in 1.5 mL of chloroform, and apply on a
25 × 3–cm column packed with 20 g of 230 to 400 mesh silica gel. Elute the column
with 300 mL chloroform, collecting 10- to 12-mL fractions.
14. Analyze fractions by TLC (APPENDIX 3D) on standard silica gel plates. Develop TLC
plates with 9:1 (v/v) chloroform/methanol.
15. Combine all fractions that contain the desired product (Rf = 0.79). Evaporate the
solvents under reduced pressure (15 to 20 mmHg) with the temperature of the water
bath not exceeding 35°C. Dissolve the residue in dry toluene and evaporate the
solvent. Store the pure product S.3d (a pale yellow oil) in a tightly closed vessel.
Approximately 0.95 g (90% to 95% yield) should be isolated. MS. (+FAB) m/z 1041.6 (M+,
1%), m/z 1042.6 (M++1, 0.6%), m/z 303.2 (DMTr+, 100%). Elemental analysis(found/cal-
culated): C 63.60%/63.44%, H 5.78%/5.52%, N 7.77%/8.08%, P 2.72%/2.98%, S
5.78%/6.15%. The diastereomeric composition, 31P NMR chemical shifts, and TLC pa-
rameters (HP-TLC plates) of S.3d are given in Table 4.17.1.
Separate diastereomers of S.3a to d
16. The day before separation, load a 30 × 2–cm column with a degassed suspension of
∼20 g of silica gel (Merck 60H, particle size 5 to 40 µm) in ∼100 mL of the appropriate
mixture of solvents:
2:1:0.003 (v/v/v) ethyl acetate/butyl acetate/pyridine for dA and dC
 derivatives
1:2:0.003 (v/v/v) ethyl acetate/butyl acetate/pyridine for dG derivative
1:1:0.002 (v/v/v) butyl acetate/benzene/pyridine for T monomer.
Gently cover the top surface of the gel with a disc of Whatman no.1 filter paper of
diameter close to the inside diameter of the column. Flush the column with 150 mL
of the eluant. Maintain a 2- to 3-mm layer of eluant over the gel.
IMPORTANT NOTE: Because the differences in chromatographic mobilities of P-dia-
stereomers are very small, the glass frit must be mounted within the cylindrical part of the
column to assure undisturbed, laminar flow of the eluant. To achieve good resolution, the
column should be packed with the silica gel suspension at least 24 hr before chromatog-
raphy. Since isocratic elution is used for the separation, the same column may be used for
two to three consecutive separations of a given monomer.
17. Dissolve ∼300 mg of a monomer (mixture of diastereomers) in 1.5 mL of the
appropriate eluant (see step 16) and apply gently on the gel.
18. Elute the column with 300 mL of appropriate eluant and collect 10- to 12-mL
fractions. Analyze fractions by TLC on HP-TLC plates (Table 4.17.1). Combine
appropriate fractions and concentrate to dryness under reduced pressure (15 to 20
mmHg) with the temperature of the water bath not exceeding 35°C.
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19. Evaporate the pure diastereomers twice with anhydrous toluene, with exclusion of
moisture, and store in a tightly closed vessel for up to 1 month at room temperature.
Typically, for dA, dT, and dC monomers, one passage gives 75% to 80% separated
diastereomers of 96% to 100% diastereomeric purity, as assessed by 31P NMR. For the dG
derivative, the “fast” isomer is usually obtained in lower yield (28% to 30%, 100%
diastereomeric purity) while the “slow” isomer is obtained in ∼50% yield, but only of 90%
diastereomeric purity, and must be rechromatographed.
ALTERNATE
PROTOCOL 2
SYNTHESIS OF 5′-O-DMTr-DEOXYRIBONUCLEOSIDE-3′-O-(2-OXO-spiro-
4,4-PENTAMETHYLENE-1,3,2-OXATHIAPHOSPHOLANE)S
5′-O-DMTr-deoxyribonucleoside-3′-O-(2-oxo-spiro-4,4-pentamethylene-1,3,2-oxa-
thiaphospholane)s (S.4) are synthesized from their corresponding 2-thio monomers (S.3;
see Basic Protocol 2) and can be used to elongate PS-oligos obtained via the oxathiaphos-
pholane approach and thereby generate short unmodified oligonucleotide segments. This
goal cannot be achieved using standard phosphoramidite chemistry because, during the
routine oxidation step by means of I2/water/pyridine, the diester phosphorothioate link-
ages already present in the oligomer would undergo PS-to-PO conversion. The oligonu-
cleotide synthesis protocol differs from that used for the synthesis of PS-oligos in the
following ways: (1) because of their relatively low stability, the 2-oxo-monomers should
not be repurified before synthesis (see Basic Protocol 3, step 1); and (2) the amount of
DBU necessary for condensation (step 16) may be reduced by 50%.
Materials
5′-O-DMTr-deoxyribonucleoside-3′-O-(2-thio-spiro-4,4-pentamethylene-1,3,2-
oxathiaphospholane)s (S.3; see Basic Protocol 2)
Silica gel 60, 230 to 400 mesh
Acetonitrile, anhydrous
Argon (or, optionally, nitrogen), dry
Selenium dioxide, anhydrous (dried overnight at high vacuum)
95:5 (v/v) chloroform/methanol (distill chloroform with 1 mL pyridine per L)
Two-neck 10-mL round-bottom flask
High-vacuum valve (e.g., Rotaflo, Quickfit)
Rubber septum
High-vacuum oil pump
10-µmol-scale DNA synthesis column
1- to 2-mL polypropylene syringes with luer ends
5-mL gas-tight syringe
TLC silica gel plates with UV indicator (Merck; also see APPENDIX 3D)
10-mL gas-tight syringe
Luer male-to-male adapter
Additional reagents and equipment for thin-layer chromatography (TLC; APPENDIX 3D)
CAUTION: Selenium dioxide is toxic.
1. Place ∼300 mg of 5′-O-DMTr-deoxyribonucleoside-3′-O-(2-thio-spiro-4,4-pen-
tamethylene-1,3,2-oxathiaphospholane) (S.3) in a two-neck 10-mL round-bottom
flask containing a magnetic stir bar, with a high-vacuum valve in one joint and a
rubber septum in the other, and dry overnight at high vacuum (0.01 mmHg; provided
by high-vacuum oil pump).
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2. Assemble a 10-µmol-scale DNA synthesis column filled to 80% of its volume with
silica gel 60 (230 to 400 mesh). Wash the gel three times, each time with 5 mL
anhydrous acetonitrile. Apply a stream of dry argon and continue drying for 15 to 20
min after the gel loosens. Close both ends of the column with two 1- to 2-mL luer
syringes to eliminate contact with atmospheric moisture.
The dryness of the gel in the column is crucial for stability of the product. Every effort
should be made to protect the dried gel from moisture.
3. Close the vacuum valve on the flask containing dried S.3 and fill the flask with dry
argon.
4. Using a 5-mL gas-tight syringe, add 4 mL of anhydrous acetonitrile.
5. With continuous flow of dry argon, remove the vacuum valve and add, in several
portions, ∼80 mg selenium dioxide.
6. Monitor the progress of the reaction by TLC (APPENDIX 3D) on silica gel plates. Develop
TLC plates with 95:5 (v/v) chloroform/methanol (see Table 4.17.2 for Rf values of
S.4).
Because the differences in chromatographic mobilities are small, always apply the starting
material on an adjacent lane as a reference.
7. After the reaction is complete, withdraw the supernatant with a 10-mL gas-tight
syringe and remove the needle.
8. Attach a luer male-to-male adapter to the bottom of the silica gel column and gently
load the withdrawn supernatant at the top. Collect the effluent in a dry flask with
continuous flow of dry argon. Wash the silica gel with 1 to 2 mL of dry acetonitrile.
As filtration progresses, an orange layer of selenium compounds moves through the gel to
the bottom of the column. Stop the filtration when the layer reaches two-thirds of the column
length from the top.
9. Replace the high-vacuum valve on the flask and evaporate acetonitrile at high
vacuum. Apply the vacuum slowly while shaking the flask continuously until the oil
residue makes a foam.
5′-O-DMTr-deoxyribonucleoside-3′-O-(2-oxo-spiro-4,4-pentamethylene-1,3,2-oxathia-
phospholane)s (S.4) are unstable and should be used for synthesis within a few hours after
preparation. They are typically isolated at 40% to 55% yield. Their 31P NMR chemical
shifts and TLC parameters are reported in Table 4.17.2.
Table 4.17.2 Characteristics of the 5′-O-DMTr-deoxyribonucleoside-3′-O-(2-oxo-spiro-4,4-
pentamethylene-1,3,2-oxathiaphospholane)sa
Base Yield (%) δP(ppm, CD3CN) Rf (TLC)
b
T (4a) 55 44.7, 44.3 0.71
ABz (4b) 41 45.1, 44.9 0.71
CBz (4c) 45 44.6, 44.1 0.70
Gi-Bu,DPC (4d) 54 45.3, 44.5 0.74
aTable adapted from Stec et al. (1998) with permission from the American Chemical Society.
bTLC performed on silica gel plates with UV indicator (Merck) and a developing system of 95:5 (v/v) chloroform/meth-
anol. The 2-oxo-monomers migrate slightly more slowly than their 2-thio-precursors.
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BASIC
PROTOCOL 3
MANUAL SOLID-PHASE SYNTHESIS OF STEREODEFINED
OLIGO(NUCLEOSIDE PHOSPHOROTHIOATE)S
Synthesis of oligo(nucleoside phosphorothioate)s using the oxathiaphospholane method
can be performed either in a standard 1-µmol column (1-µmol-scale synthesis) or in a
reassembled OPC column (2-µmol scale; see below). Because of the strong base used for
the condensation step (1,4-diazabicyclo[5.4.0]undec-7-ene), a sarcosinylated solid sup-
port must be used (see Support Protocol 2). Typically, supports are functionalized with
25 to 40 µmol nucleoside per gram. A lower nucleoside concentration is not recom-
mended, because a larger amount of support will be necessary to achieve the synthesis at
the recommended scale, and may not leave enough space for efficient mixing with
incoming reagents. The condensation step is extremely sensitive even to trace amounts
of moisture. Therefore, the acetonitrile to be used as a solvent for DBU, and deoxyribonu-
cleoside oxathiaphospholane monomers should be dried over P2O5 (5 g/L) and distilled
under reduced pressure (∼200 mmHg) through a 20-cm Vigreux column with exclusion
of moisture under an atmosphere of dry argon. At least one-third of the initial volume
must remain in the flask. Acetonitrile dried in this way must be transferred using a
gas-tight syringe under an atmosphere of dry argon, or by the vacuum line technique (see
Support Protocol 1).
 This protocol describes a 2-µmol-scale synthesis. The synthesis proceeds from the 3 ′-end
to the 5 ′-end of the sequence. The first nucleoside from the 3′-end is attached to the solid
support. To avoid mistakes, the investigator is recommended to have a synthesis step check
list to check off each of the executed steps during consecutive synthetic cycles, as
illustrated in Table 4.17.3 for synthesis of the sequence 5′-TGACTGCA-3′. Notably, after
the last condensation step, the capping procedure is not executed.
Materials
Deoxyribonucleoside oxathiaphospholane monomers (see Basic Protocol 2 and/or
Alternate Protocol 2)
Chloroform (optional), distilled with 1 mL pyridine per L
Toluene, anhydrous
Low-pressure argon or nitrogen, dried (see recipe)
Sarcosinylated solid support functionalized with a nucleoside (first from the 3′ end
of sequence to be synthesized) at a concentration ranging from 20 to 30 µmol/g
support (see Support Protocol 2)
Capping reagent A: 1:1:8 (v/v/v) acetic anhydride/pyridine/tetrahydrofuran (THF)
Capping reagent B: 7 g 4-dimethylaminopyridine/93 mL THF
Anhydrous acetonitrile (H2O < 20 ppm; see recipe) in bottle with rubber septum,
with dry gas delivered inside through a line ending in a needle
Table 4.17.3 Sample Check List for Oligonucleotide Synthesis (Sequence 5′-TGACTGCA-3′)
Nucleoside monomer Detritylation Coupling Capping
— — — √
C-OTP monomer √ √
G-OTP monomer
T-OTP monomer
C-OTP monomer
A-OTP monomer
G-OTP monomer
T-OTP monomer —
Supplement 15 Current Protocols in Nucleic Acid Chemistry
4.17.18
Synthesis of
Phosphorothioate
Oligonucleotides
with Stereo-
defined Linkages
Detritylating reagent: 3.5% (w/v) dichloroacetic acid in methylene chloride
Acetonitrile, HPLC grade (Baker)
1:4.5 (v/v) 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in anhydrous acetonitrile
(H2O <20 ppm)
Methylene chloride
Aqueous ammonia, concentrated (Baker)
10 × 3–cm chromatography column packed with 10 g 230- to 400-mesh silica gel
60 (optional)
4-mL sample vials with open-top screw caps with Teflon-faced rubber septa
19- to 22-G, 1- to 1.5-in. luer-lock needles
Vacuum desiccator (≤0.05 mmHg; provided by high-vacuum oil pump) with
condenser cooled by liquid N2
1-, 2-, and 5-mL all-polypropylene luer-lock syringes
19- to 22-G, 2- to 3-in. luer-lock needles with blunt 90° tips
Columns for DNA synthesis:
 For 1-µmol scale: Applied Biosystems DNA synthesis column (cat. no. 400407),
empty, 1.0 µmol crimp-style
 For 2-µmol scale: emptied and reassembled Applied Biosystems oligonucleotide
purification cartridge (OPC; cat. no. 400771)
Column filters (two for each column; Applied Biosystems, cat. no. 400059)
Aluminum seals (caps; two for each column; Aldrich cat. no. Z11413-8; Wheaton
aluminum cap, 13 mm, tear-off)
Crimper for aluminum seals (Aldrich, cat. no. z 11423)
Polypropylene (or other chemically inert) luer male-to-male adapter
100- and 500-µL gas-tight syringes (Hamilton)
Glass drying tube (∼2-cm i.d., 25-cm length), with three-way valve (or two
independent valves) at the top and a rubber septum at the opposite side
High-vacuum (0.05 mmHg) oil pump
500-mL filtering flask capped with a rubber septum pierced with a 3- to 4-mm i.d.
hole
Water aspirator with a manostat
Two waste bottles: one for chlorinated waste (methylene chloride, detritylating
reagent) and another for water-miscible wastes (acetonitrile, capping reagents A
and B)
60°C water bath (optional)
Speedvac concentrator with vacuum provided by water aspirator
19- to 22-G, 4- to 5-in. luer-lock needles with blunt 90° tips
Additional reagents and equipment for column chromatography (optional;
APPENDIX 3E) and purification of oligonucleotides (UNITS 10.3-10.5)
CAUTION: The drying tube must be tested to make sure that it is safe for high-vacuum
usage, i.e., at a pressure lower than 0.05 mmHg.
Prepare monomers for synthesis
1. If the deoxyribonucleoside oxathiaphospholane monomers (S.3 only) have been
stored for more than one week, repurify them by flash chromatography (APPENDIX 3E)
on a 10 × 3–cm silica gel column using chloroform (distilled with pyridine) as eluant.
Concentrate appropriate fractions with exclusion of moisture. Coevaporate the resi-
due twice with anhydrous toluene and apply high vacuum to generate a foam.
Repurification is necessary to keep repetitive yield at 92% to 94%. The 2-oxo-monomers
(S.4) should not be repurified in this manner, and should be used within a few hours of
synthesis (see Alternate Protocol 2).
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2. If necessary, use a spatula to disaggregate the foam of oxathiaphospholane monomers.
3. Put ∼30 mg of given monomer (S.3 or S.4) in an appropriately marked 4-mL sample
vial (one vial for each condensation step to be performed) and cover tightly with an
open-top screw cap with a Teflon-faced rubber septum. Pierce each septum with a
19- to 22-G, 1- to 1.5-in. luer-lock needle.
Before the vials are stored in the desiccator (step 4), be sure that none of the needles became
clogged during piercing. This can be done by temporarily inserting a second needle to
deliver a stream of dry argon to the vial. The unrestricted flow of argon from the first needle
should be easily sensed.
4. Dry monomers in a vacuum desiccator at ≤0.05 mmHg for at least 12 hr. After the
drying is complete, fill the desiccator with dry argon, open it cautiously, and
immediately remove the needles from the vials.
The condenser should be free of any solvents before the drying starts. It is recommended
that the condenser be cooled with liquid nitrogen. It is imperative that the oil pump and
the whole vacuum system intended for drying monomers be free of acidic impurities such
as acetic or hydrochloric acid. Traces of acids would partially detritylate the monomers.
Perform initial setup procedures
5. Prepare and place a permanent mark upon all-polypropylene syringes for capping (2
mL), detritylation (5 mL), washing with acetonitrile (5 mL), and washing with
methylene chloride (5 mL). Fit each with a 19- to 22-G, 2- to 3-in. needle with a blunt
90° tip.
Use the syringes only for designated purposes, as cross-contamination may lead to poor
synthesis yields. The needles should be blunted for safety reasons.
6. Fill a column with an appropriate support for synthesis and assemble it. Be sure to
insert column filters at both ends of the column. Secure the aluminum caps with a
crimper. Remove the middle part of each aluminum cap. Insert a luer male-to-male
adapter into one outlet of the column and attach the outlet needle (19- to 22-G, 4- to
5-in. with a blunt 90° tip).
Do not hesitate to apply significant force to secure aluminum caps. This is crucial for
avoiding leakage of chemicals during synthesis. The long outlet needle (4- to 5-in.) is more
convenient for swirling of the column during consecutive synthetic steps.
7. Set the manostat for the filtering flask at 400 to 450 mmHg.
Start synthesis cycle
8. Mix 1 mL capping reagent A and 1 mL capping reagent B in the 2-mL dedicated
syringe for capping (see step 5), remove the needle, and gently load the mixture into
the column. Continue capping for 2 min with intermittent swirling of the column.
Expel reagent from the column into a proper waste bottle.
CAUTION: Avoid undue force when pushing the plunger. Excessively fast loading or
expelling of the reagents may damage the column filters.
9. Fill the dedicated 5-mL syringe for acetonitrile washing (see step 5) with HPLC-grade
acetonitrile. Remove the needle and flush the column with intermittent swirling.
Collect the effluent in the proper waste bottle. Expel the remaining liquid, then insert
the outlet needle of the column through the septum on the top of the filtering flask,
deliver a stream of argon from the top of the column, and gently apply suction to the
filtering flask. Continue drying until the support in the column becomes loose.
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10. Fill the dedicated 5-mL syringe for detritylation (see step 5) with detritylating
reagent. Remove the needle and flush the column with intermittent swirling. Collect
the effluent in the proper waste bottle or in a test tube for quantitative cationic DMTr
analyses. Expel the remaining liquid.
IMPORTANT NOTE: Upon contact with the support, the detritylation solution becomes
red due to the presence of DMTr cations removed from the nucleoside. If at the end of
delivery the effluent is still colored, continue detritylation with an additional volume of
fresh reagent to complete the detritylation process.
11. Wash the support with 5 mL of acetonitrile and dry it as described in step 9.
12. Put the column and gas-tight syringes (500 µL and 100 µL) in the drying tube, gently
apply high vacuum, and continue drying for 10 min. Close the vacuum valve on the
drying tube and deliver dry gas to the tube. Take the syringes out of the tube (leave
the column inside), close the tube with the septum, close the gas valve, and apply
vacuum again. Use the syringes only for designated purposes.
CAUTION: Do not allow the rubber septum to be expelled from the bottom of the tube by
excessively high gas pressure.
13. Withdraw 300 µL of dry acetonitrile (H2O <20 ppm) using the 500-µL gas-tight
syringe and add the solvent to the vial containing the appropriate oxathiaphospholane
monomer.
14. Close the vacuum valve on the drying tube and deliver dry gas to the tube. Take the
column out of the tube, close the tube with the septum, and close the gas valve. Insert
a dry 1-mL syringe into the inlet of the column.
15. Withdraw 90 µL of 1:4.5 (v/v) DBU/acetonitrile using the 100-µL gas-tight syringe
and add the reagent to the vial containing the dissolved oxathiaphospholane mono-
mer. Mix the contents of the vial for a few seconds.
16. Pierce the septum of the vial with the needle of the column and, using the syringe
attached to the column, suck up the contents of the vial to fill the column. Swirl the
column intermittently for 10 min. Expel the liquid to the waste bottle.
17. Wash the support with 5 mL of methylene chloride, followed by 5 mL of HPLC-grade
acetonitrile, and dry as described in step 9.
Complete synthesis cycle
18. Repeat steps 8 to 17 with each successive monomer until elongation is complete.
19. Execute a routine cleavage of the product from the support using a few milliliters of
concentrated aqueous ammonia for 2 hr, followed (if necessary) by heating of the
ammoniacal solution in a tightly closed vessel at 55°C for 12 hr to remove nucleo-
base-protecting groups.
20. Concentrate the sample under reduced pressure in a Speedvac concentrator using a
water aspirator.
21. Purify the oligonucleotide according to published protocols (UNITS 10.3-10.5).
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SUPPORT
PROTOCOL 2
ATTACHMENT OF NUCLEOSIDE 3′-O-SUCCINYL HEMIESTERS TO SAR-
COSINYLATED SOLID-PHASE SUPPORT
This protocol attaches 5′-O-DMTr-N-protected nucleoside-3′-O-succinyl hemiesters to
long-chain alkylamine controlled-pore glass (LCAA-CPG) through a sarcosinyl linker.
Since 5′-O-DMTr-N-protected nucleoside-3′-O-succinate hemiesters are commercially
available, their syntheses are not described. Alternatively, one may prepare them by
coupling succinic anhydride with a protected nucleoside according to published proce-
dures (see UNIT 3.2 and references therein).
Materials
Long-chain alkylamine controlled-pore glass (LCAA-CPG) beads (80 to 120
mesh, 500 Å; Sigma)
9-Fluorenylmethoxycarbonyl (Fmoc)–sarcosine monohydrate (Fluka)
Argon (or, optionally, nitrogen), dry
1,3-Dicyclohexylcarbodiimide (DCC; Aldrich)
Dimethylformamide (DMF), anhydrous
Pyridine, anhydrous
1:1:1 (v/v/v) acetonitrile/methanol (reagent grade)/pyridine
Acetonitrile, anhydrous
10% (v/v) piperidine in pyridine
5′-O-DMTr-N-protected nucleoside-3′-O-succinyl hemiester (Sigma)
25-mL two-neck round-bottom flasks
High-vacuum valve (e.g., Rotaflo, Quickfit)
Rubber septum
High-vacuum oil pump
1-mL and 10-mL gas-tight syringes
Buchner funnel with glass frit
Filter flask
Vacuum source (e.g., water aspirator)
50-mL Erlenmeyer flask with stopcock
CAUTION: 1,3-Dicyclohexylcarbodiimide can cause skin or eye irritation and allergic
reactions. Use appropriate protection.
Couple Fmoc-sarcosine to LCAA-CPG
1. Place 2 g LCAA-CPG beads and 0.5 g (1.6 mmol) Fmoc-sarcosine in a 25-mL
two-neck round-bottom flask containing a magnetic stir bar, with a high-vacuum
valve in one joint and a rubber septum in the other, and dry overnight at high vacuum
(0.01 mmHg; provided by a high-vacuum oil pump). At the end of drying, deliver dry
argon (or nitrogen) to the flask through the septum.
2. Open the flask, quickly add 0.5 g (2.4 mmol) DCC, and close the flask.
3. Using gas-tight syringes, add 5 mL anhydrous DMF followed by 0.5 mL anhydrous
pyridine.
4. Stir the mixture at room temperature for 12 hr.
5. Transfer the suspension to a fritted-glass Buchner funnel and filter off the solution.
6. Wash support on the funnel three times, each time with 50 mL of 1:1:1 (v/v/v)
acetonitrile/methanol/pyridine with gentle suction.
7. Wash with 50 mL acetonitrile and continue suction for 2 to 3 min.
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8. Transfer the support to a 50-mL Erlenmeyer flask, add 20 mL of 10% piperidine in
pyridine, and seal the flask. Shake occasionally over a 30-min period. Decant the
liquid.
9. Filter and wash as in steps 5 to 7.
10. Allow the support to dry at room temperature in a fume hood.
Couple nucleoside-3′-O-succinyl hemiesters to LCAA-CPG-Sar
12. Place 2 g LCAA-CPG-Sar and ∼0.35 g (∼0.5 mmol) 5′-O-DMTr-N-protected nucleo-
side-3′-O-succinyl hemiester in a 25-mL two-neck round-bottom flask containing a
magnetic stir bar, with a high-vacuum valve in one joint and a rubber septum in the
other, and dry overnight at high vacuum (0.01 mmHg; provided by a high-vacuum
oil pump). At the end of drying, deliver dry argon (or nitrogen) to the flask through
the septum.
13. Open the flask, quickly add 0.2 g (1 mmol) DCC, and close the flask.
14. Using gas-tight syringes, add 10 mL anhydrous DMF, followed by 0.8 mL anhydrous
pyridine.
15. Stir the mixture at room temperature for 24 hr.
16. Filter and wash as in steps 5 to 7.
17. Allow the support to dry at room temperature in a fume hood.
Typically, using long-chain alkylamine controlled-pore glass, 80 to 120 mesh, 500 Å
(Sigma) a concentration of 25 to 40 mol of nucleoside per gram of support is obtained.
The support should be stored in a tightly closed vessel in the dark. It is stable for several
years at room temperature.
IMPORTANT NOTE: The support should be prevented from contact with acidic vapors to
avoid detritylation.
REAGENTS AND SOLUTIONS
Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see
APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Acetonitrile, anhydrous (H2O <20 ppm)
Dry acetonitrile over 5 g P2O5 per L for at least 24 hr, then distill under reduced
pressure through a 20-cm Vigreux column with exclusion of moisture under an
atmosphere of dry argon; at least one-third of the initial volume must remain in the
flask. Transfer to reaction vessels using gas-tight syringes under dry argon, or by
vacuum line technique (see Support Protocol 1).
IMPORTANT NOTE: For condensation steps in Basic Protocol 3, the water content of
acetonitrile must be <20 ppm as measured by the Karl Fischer technique. “DNA/RNA
synthesis grade” acetonitrile supplied by leading manufacturers is usually not suitable for
this purpose unless dried as above.
Low-pressure argon or nitrogen, dried
Dry the gas by passing it through a 0.5- to 0.7-m-long column (3- to 4-cm i.d.) filled
with blue indicator silica gel (Aldrich cat. no. 336815), then through a similar
column filled with granular molecular sieves covered with P2O5. Delivery of inert
gas under a slight positive pressure is accomplished by attaching a source of gas via
tubing to a T-shaped glass connector. One arm of the connector is attached to the
inlet of the first drying column; the other arm is connected to a rubber balloon. After
the balloon is inflated up to a diameter of 40 to 50 cm, the valve on the tank regulator
is closed, and the internal pressure of the balloon will be sufficient to assure
appropriate flow of the gas. The balloon needs to be reinflated from time to time.
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The outlet of the second drying column should be attached through a bubbler
(partially filled with mineral oil) to a manifold with 2 to 3 delivery lines, each ending
with a valve and a male luer adapter.
Typically, argon has lower water content than nitrogen, therefore the drying columns have
a longer life-time if argon gas is used.
COMMENTARY
Background Information
Oligo(nucleoside phosphorothioate)s are
congeners of natural oligonucleotides where
one of the two nonbridging oxygens in each
internucleotide phosphate is replaced by sulfur.
By virtue of asymmetry at the phosphorus
atom, these constitute a mixture of P-dia-
stereomers, and syntheses of such molecules
with predetermined P-chirality at each internu-
cleotide bond are challenging. While the stere-
ocontrolled synthesis of PS-oligos is an art,
even more challenging are studies on the prop-
erties of such P-stereodefined congeners,
mainly with respect to their interactions with
other biomolecules such as natural DNA, RNA,
and proteins. The affinity of PS-oligos towards
DNA and RNA seems to be dictated mainly by
base pairing, but is also affected, to a certain
extent, by their P-chirality. Notably, intuitive
speculations (Zon et al., 1987) or molecular
mechanics calculations (Jaroszewski et al.,
1992; Hartmann et al., 1999) have led to con-
clusions contradicting the results of melting
experiments performed with heteroduplexes in-
volving P-stereodefined PS-oligos (Boczk-
owska et al., 2002). This underscores the im-
portance of experimental verification of such
hypotheses, which is possible only through
access to stereodefined PS-oligos.
Physicochemical studies demonstrated that
stereoregular PS-oligos of the sequence d(CG)4
of opposite configurations at phosphorus differ
significantly in their ability to adopt the Z-con-
formation in high concentrations of sodium
chloride (Boczkowska et al., 2000). Prelimi-
nary studies demonstrated that PS-oligos of
RP-configuration containing polyadenylate se-
quences are able to form unusually stable tri-
plexes with two antiparallel complementary
RNA strands. The molecular basis of this phe-
nomenon is still unknown, but the role of sulfur
in the Rp configuration is essential, as neither
[all-SP]-PS-oligomers nor unmodified DNA
oligomers are able to form corresponding tri-
plexes of comparable stability (Stec, unpub.
observ.) P-stereodefined (PS) oligos have been
used for studying the mode of action of several
bacterial and human enzymes (Koziolkiewicz
et al., 1997, 2001, 2002). The observation that
plasma 3′-exonucleases—a class of proteins
responsible for degradation of oligonucleotides
in blood—are RP-selective enzymes provided
the invaluable information that this enzymatic
activity, detrimental toward antisense therapeu-
tics, can be stopped by a single SP-phos-
phorothioate at the 3′ end of PS-oligonu-
cleotides. Besides this practical aspect, eluci-
dation of the mechanism of the nucleolytic
cleavage by 3′-exonuclease(s) provided, for the
first time, the information necessary for the
classification of this family of proteins (Koz-
iolkiewicz et al., 2002). The interactions of
phosphate groups with proteins is well docu-
mented. Therefore, the presented method for
stereodefined labeling of internucleotide phos-
phate groups with sulfur and stable oxygen
isotopes opens a new avenue for mechanistic
studies on DNA/protein interactions at atomic
resolution.
In this unit, experimental details of the
oxathiaphospholane method, developed for
stereocontrolled synthesis of oligo(nucleoside
phosphorothioate)s, are presented. The method
is based upon the synthesis of appropriately
protected nucleoside 3′-O-(2-thiono-1,3,2-
oxathiaphospholane)s and their separation into
diastereomerically pure species. It has been
demonstrated that DBU-assisted condensation
of these monomers with the 5′-OH group of a
nucleoside or growing oligonucleotide in the
iterative process of chain elongation on a solid
support is stereospecific. Stereopurity of [all-
RP]- and [all-SP]-oligonucleotides has been
validated via degradation with stereoselective
nucleases such as snake venom phosphodi-
esterase (Eckstein et al., 1979) and nuclease P1
(Eckstein et al., 1983), respectively. Additional
studies have also demonstrated that episulfide,
which is released from the ring-opening con-
densation process, does not modify growing
oligonucleotides.
One has to realize that this methodology is
laborious and costly, and suffers from numer-
ous imperfections which do not allow for the
preparation of long PS-oligonucleotides (>15-
mers). Nonetheless, the oxathiaphospholane
Supplement 14 Current Protocols in Nucleic Acid Chemistry
4.17.24
Synthesis of
Phosphorothioate
Oligonucleotides
with Stereo-
defined Linkages
method has provided many stereodefined PS-
oligonucleotides suitable for many applica-
tions, including NMR studies (Kanehara et al.,
1996; Furrer et al., 1999) and biological evalu-
ation in cell cultures, although newcomers to
the field may have found it difficult to use. It is
clear to the authors of this unit that new modi-
fied oxathiaphospholane monomers are highly
desirable, as they would not only allow im-
provement in the repetitive yield of a single
condensation step, but would also provide a
new and efficient method for protecting inter-
nucleotide phosphorothioate diesters against
oxidation, necessary for effective combination
of the oxathiaphospholane method with phos-
phoramidite chemistry. Such a combination
may provide an effective access to so-called
gap-mer or chimeric constructs (Metelev et al.,
1994; Pickering et al., 1996; Maier et al., 2000)
consisting of oligo(nucleoside phosphate)s and
P-stereodefined oligo(nucleoside phos-
phorothioate) segments. Work on these exten-
sions to the presented method is in progress.
Various attempts at stereocontrolled synthe-
sis of PS-oligos undertaken by other research
establishments have been reported, among
them efforts directed towards stereospecific
synthesis of dinucleoside 3′,5′-phos-
phorothioates (Jin et al., 1996; Jin and Just,
1998; Wada et al., 1998; Wang and Just, 1999;
Lu and Just, 2000; Oka et al., 2002), Agrawal’s
work on the synthesis of nearly stereopure
PS-oligos (Iyer et al., 1995, 1998), and the
successful stereocontrolled synthesis of long-
mers reported by Beaucage’s laboratory (Wilk
et al., 2000). These groups utilized the ingen-
ious phosphoramidite methodology originally
developed by Beaucage and Caruthers (1981).
The availability of short P-stereodefined PS-
oligos (up to pentamers) following separation
of diastereomers by means of RP-HPLC should
also be noted (Murakami et al., 1994; Tamura,
1998).
Critical Parameters and
Troubleshooting
Chemical synthesis of the phosphitylating
reagent requires some skills to prevent release
of the unpleasant odor characteristic of organo-
sulfur compounds. It is recommended that
glassware be cleaned using an oxidant, like
sodium hypochlorite or hydrogen peroxide, to
convert sulfhydryl or disulfide-containing
compounds into sulfones.
As mentioned in relevant protocols, over-
heating of the vessels during high-vacuum dis-
tillation is dangerous, as it may lead to sponta-
neous decomposition of the material inside the
vessels. One should frequently monitor the
pressure in the system during distillation and
keep temperature within the indicated range.
For the synthesis of final phosphitylating
reagent as well as for phosphitylation of nu-
cleosides, the dryness of solvents and glassware
is extremely important, because P(III) chlo-
rides react instantly with traces of water.
Like oligonucleotide synthesis via the phos-
phoramidite or H-phosphonate approach, the
dryness of monomers, solvents, and equipment
used for coupling is essential for good yields in
the oxathiaphospholane approach. Here, the
importance of this factor is further stressed
because, even with all precautions taken, the
repetitive yield of coupling is between 92% and
94%, and any further decrease in coupling
yields due to the presence of traces of water
may render oligonucleotide synthesis imprac-
tical. It is recommended that the cationic DMTr
release be quantitated after each condensation
step to check if the actual repetitive yield is
acceptable.
Anticipated Results
Synthesis of phosphitylating reagent, al-
though not trivial, should furnish the consecu-
tive products with reasonable yield (60% to
70%). The reagent is stable and can be stored
for months. The same applies to the deoxyri-
bonucleoside 2-thio-oxathiaphospholane
monomers. They can be stored in a desiccator
at room temperature for several months. Fol-
lowing flash chromatography, the material is
recovered at >95% yield, and can then be used
for oligonucleotide synthesis. Synthesis of a
15-mer PS-oligo at a 2-µmol scale usually pro-
vides 8 to 10 OD units of pure material. This is
∼5% of theoretical yield. It is important that
during HPLC purification only the upper part
of the oligonucleotide peak be collected (>40%
of peak height) to obtain a more homogenous
oligomer.
Time Considerations
Since neither the oxathiaphosphitylating re-
agent nor the oxathiaphospholane monomers
are commercially available, their preparation is
necessary and takes a considerable amount of
time. It is reasonable to assume that the synthe-
sis of 2-chloro-spiro-4,4-pentamethylene-
1,3,2-oxathiaphospholane starting from cyclo-
hexanecarboxaldehyde can be accomplished in
10 working days, provided that the technical
staff prepares, simultaneously, the necessary
anhydrous solvents.
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Phosphitylation/sulfurization of commer-
cially available, appropriately protected nu-
cleosides at 10 mmol scale, as well as prepara-
tion of sarcosinylated supports, require 10 ad-
ditional days. Separation of nucleoside
monomers into P-diastereomerically pure spe-
cies is a very important and rather difficult step.
Undoubtedly, some experience is necessary to
obtain good results. It should be emphasized
that proper loading of the chromatographic
column, as well as very careful elution and TLC
analysis of effluent, are crucial for yield and
diastereomeric purity of the resolved mono-
mers. It must also be taken into account that
separation of diastereomers is a time-consum-
ing step, as only ∼300 mg of monomer can be
applied on a single silica gel column. The 100
to 120 mg of each pure diastereomer recovered
from that amount is sufficient for 3 to 4 cou-
pling steps. To avoid delay resulting from labo-
rious chromatographic purifications, it is good
practice to stockpile pure diastereomers, as they
are chemically stable and can be stored for long
periods of time.
Once the monomers are made, the synthesis
of PS-oligos proceeds much more rapidly, and
typically one oligomer can be made and puri-
fied within 4 to 5 days. Usually, during manual
synthesis, one can accomplish 8 to 10 couplings
daily. If the synthesis is to be continued on the
next day, it should be interrupted after the
capping step, followed by washing and drying
of the support. The synthetic column should
then be stored in a desiccator.
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